Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Jan;75(1):92–97.

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries

C Trenkwalder 1, D Garcia-Borreguero 1, P Montagna 1, E Lainey 1, A W de Weerd 1, P Tidswell 1, G Saletu-Zyhlarz 1, W Telstad 1, L Ferini-Strambi 1
PMCID: PMC1757460  PMID: 14707315

Abstract

Objective: To assess the efficacy, safety, and tolerability of ropinirole in the treatment of patients with restless legs syndrome.

Methods: A 12 week, prospective, double blind, randomised comparison involving 284 patients from 10 European countries. All participants had a score of ⩾15 on the international restless legs scale (IRLS). Patients were randomised (1:1) to receive either ropinirole 0.25–4.0 mg once daily or placebo. The primary efficacy end point was mean change from baseline to week 12 in total IRLS score. Global improvements (clinical global impression (CGI) scale) and improvements in sleep, health related quality of life (QoL; using generic and disease specific measures), work, and other activities were also assessed.

Results: 112/146 patients (76.7%) taking ropinirole and 109/138 (79.0%) taking placebo completed the study. Improvement in IRLS at week 12 with ropinirole (mean (SD) dose, 1.90 (1.13) mg/day) was greater than with placebo (mean (SE): -11.04 (0.719) v -8.03 (0.738) points; adjusted difference = -3.01 (95% confidence interval (CI), -5.03 to -0.99); p = 0.0036). More patients in the ropinirole group (53.4%) showed improvement on the CGI scale at week 12 than in the placebo group (40.9%; adjusted odds ratio = 1.7 (1.02 to 2.69); p = 0.0416). Significant differences on both IRLS and CGI scales favouring ropinirole were apparent by week 1. Ropinirole was also associated with significantly greater improvements in sleep and QoL end points. The most common adverse events were nausea and headache.

Conclusions: Ropinirole improves restless legs syndrome compared with placebo, with benefits apparent by week 1. It is generally well tolerated.

Full Text

The Full Text of this article is available as a PDF (389.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen R. P., Earley C. J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996 Apr;19(3):205–213. doi: 10.1093/sleep/19.3.205. [DOI] [PubMed] [Google Scholar]
  2. Brodeur C., Montplaisir J., Godbout R., Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology. 1988 Dec;38(12):1845–1848. doi: 10.1212/wnl.38.12.1845. [DOI] [PubMed] [Google Scholar]
  3. Danoff S. K., Grasso M. E., Terry P. B., Flynn J. A. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest. 2001 Jul;120(1):313–316. doi: 10.1378/chest.120.1.313. [DOI] [PubMed] [Google Scholar]
  4. Earley C. J., Yaffee J. B., Allen R. P. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology. 1998 Dec;51(6):1599–1602. doi: 10.1212/wnl.51.6.1599. [DOI] [PubMed] [Google Scholar]
  5. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. 2002 Nov;3 (Suppl):S23–S25. doi: 10.1016/s1389-9457(02)00144-2. [DOI] [PubMed] [Google Scholar]
  6. Grisold W., Heimans J. J., Postma T. J., Grant R., Soffietti R., Neuro-Oncology Panel of the EFNS The position of the neurologist in neuro-oncology. Eur J Neurol. 2002 May;9(3):201–205. doi: 10.1046/j.1468-1331.2002.00411.x. [DOI] [PubMed] [Google Scholar]
  7. Montplaisir J., Denesle R., Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol. 2000 May;7 (Suppl 1):27–31. doi: 10.1046/j.1468-1331.2000.0070s1027.x. [DOI] [PubMed] [Google Scholar]
  8. Ondo W. Ropinirole for restless legs syndrome. Mov Disord. 1999 Jan;14(1):138–140. doi: 10.1002/1531-8257(199901)14:1<138::aid-mds1023>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  9. Phillips B., Young T., Finn L., Asher K., Hening W. A., Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med. 2000 Jul 24;160(14):2137–2141. doi: 10.1001/archinte.160.14.2137. [DOI] [PubMed] [Google Scholar]
  10. Rothdach A. J., Trenkwalder C., Haberstock J., Keil U., Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology. 2000 Mar 14;54(5):1064–1068. doi: 10.1212/wnl.54.5.1064. [DOI] [PubMed] [Google Scholar]
  11. Saletu B., Gruber G., Saletu M., Brandstätter N., Hauer C., Prause W., Ritter K., Saletu-Zyhlarz G. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology. 2000;41(4):181–189. doi: 10.1159/000026658. [DOI] [PubMed] [Google Scholar]
  12. Saletu M., Anderer P., Saletu B., Hauer C., Mandl M., Oberndorfer S., Zoghlami A., Saletu-Zyhlarz G. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology. 2000;41(4):190–199. doi: 10.1159/000026659. [DOI] [PubMed] [Google Scholar]
  13. Staedt J., Hünerjäger H., Rüther E., Stoppe G. Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication. J Neural Transm (Vienna) 1998;105(2-3):265–268. doi: 10.1007/s007020050055. [DOI] [PubMed] [Google Scholar]
  14. Stiasny K., Wetter T. C., Winkelmann J., Brandenburg U., Penzel T., Rubin M., Hundemer H. P., Oertel W. H., Trenkwalder C. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology. 2001 May 22;56(10):1399–1402. doi: 10.1212/wnl.56.10.1399. [DOI] [PubMed] [Google Scholar]
  15. Trenkwalder C., Stiasny K., Pollmächer T., Wetter T., Schwarz J., Kohnen R., Kazenwadel J., Krüger H. P., Ramm S., Künzel M. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep. 1995 Oct;18(8):681–688. doi: 10.1093/sleep/18.8.681. [DOI] [PubMed] [Google Scholar]
  16. Ulfberg J., Nyström B., Carter N., Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord. 2001 Nov;16(6):1159–1163. doi: 10.1002/mds.1209. [DOI] [PubMed] [Google Scholar]
  17. Walters A. S. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord. 1995 Sep;10(5):634–642. doi: 10.1002/mds.870100517. [DOI] [PubMed] [Google Scholar]
  18. Wetter T. C., Stiasny K., Winkelmann J., Buhlinger A., Brandenburg U., Penzel T., Medori R., Rubin M., Oertel W. H., Trenkwalder C. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology. 1999 Mar 23;52(5):944–950. doi: 10.1212/wnl.52.5.944. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES